Plain-English translation of NCT07674654 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a long-term safety study for people who have already participated in an earlier trial of , a new medication being developed to treat acute migraine attacks. Researchers want to understand how safe this medication is and how well people tolerate it when they use it over time. The study will track about 1,000 participants who took the medication in the initial trial and are now entering this follow-up phase.
Before the FDA can approve a new migraine medication, researchers need to know not just that it works, but that it remains safe and tolerable when people use it repeatedly over longer periods. This study gathers that crucial long-term safety information.
You likely qualify if…
You likely don't qualify if…
As a participant, you would continue using the medication to treat your migraine attacks as they occur, rather than taking it daily. You would track your symptoms and how you respond to the treatment using a smartphone app with daily check-in reminders. You'll attend study visits at the clinic and complete questionnaires about your experience, your migraines, and any side effects you notice over the course of the study.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
United States